Kyle Coleman, MD
Dermatology · Thibodaux, LANPI 1588777361
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (52.2%), food and beverage and education — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by Galderma Laboratories, L.p. at 54.1% of the total. 2025 is the largest year on record at $7,854, more than ten times the $469 reported in 2019.
Across 275 payments — averaging $44.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Galderma Laboratories, L.p.$7K
- AbbVie$1K
- Johnson & Johnson$721
- Pfizer$518
- Regeneron Healthcare Solutions, Inc.$385
- UCB, Inc.$364
- plus $2K from 23 others
Across 79 payments — averaging $18,591 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$1.4M
- Galderma Research & Development, LLC$24K
- E.r. Squibb & Sons, L.L.C.$6K
What the payments were for
- Consulting fees$6,40052%
- Food & beverage$5,54945%
- Education$3062%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Galderma Laboratories, L.p. | 7 | $6,624 |
| AbbVie(2 entities) | 87 | $1,467 |
| Johnson & Johnson(2 entities) | 28 | $721 |
| Pfizer | 33 | $518 |
| Regeneron Healthcare Solutions, Inc. | 18 | $385 |
| UCB, Inc. | 13 | $364 |
| Sanofi | 14 | $327 |
| Amgen | 11 | $220 |
| Revance Therapeutics, Inc. | 4 | $220 |
| E.r. Squibb & Sons, L.L.C. | 11 | $216 |
| Novartis | 13 | $213 |
| Hill Dermaceuticals, Inc. | 1 | $200 |
| Incyte Corporation | 7 | $147 |
| Merz North America, Inc. | 3 | $88 |
| Endo Pharmaceuticals Inc. | 1 | $83 |
| Mayne Pharma Commercial LLC | 2 | $58 |
| Sun Pharmaceutical Industries Inc. | 3 | $53 |
| Dermavant Sciences, Inc. | 3 | $52 |
| LEO Pharma Inc. | 3 | $47 |
| Almirall LLC | 2 | $43 |
| Organon | 2 | $30 |
| Lilly USA, LLC | 2 | $30 |
| VYNE Pharmaceuticals Inc. | 1 | $30 |
| Boehringer Ingelheim | 1 | $29 |
| Genentech USA, Inc. | 1 | $24 |
| Arcutis Biotherapeutics, Inc. | 1 | $19 |
| Biocon Biologics Inc | 1 | $17 |
| Mission Pharmacal Company | 1 | $16 |
| Bristol Myers Squibb | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,255 in reported general payments places this provider in the 80th percentile of 189 dermatology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TremfyaGuselkumab | 18 | $249,249 |
| Dupixent PenDupilumab | 53 | $218,693 |
| SotyktuDeucravacitinib | 16 | $109,223 |
| OtezlaApremilast | 11 | $62,649 |
| Betamethasone Dipropionate | 145 | $6,399 |
| Mometasone Furoate | 258 | $4,387 |
| Ketoconazole | 317 | $4,351 |
| Ammonium Lactate | 154 | $3,246 |
| Triamcinolone Acetonide | 215 | $2,842 |
| Metronidazole | 60 | $2,611 |
| Halobetasol Propionate | 35 | $2,572 |
| Fluocinonide | 32 | $1,713 |
| Clobetasol Propionate | 44 | $1,625 |
| Doxycycline Monohydrate | 65 | $1,553 |
| Tretinoin | 14 | $1,437 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonTremfya | $721 | $249,24918 claims |
| E.r. Squibb & Sons, L.L.C.Sotyktu | $216 | $109,22316 claims |
| AmgenOtezla | $220 | $62,64911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 189 dermatology providers in Louisiana.
Other dermatology in Thibodaux
- Ryan MatherneThibodaux$9K
- Katherine HolcombMetairie$411K
- William ClaiborneNew Orleans$374K
- Blair BuddenLafayette$329K
- Erin BohNew Orleans$277K
- Mara HaseltineNew Orleans$276K
- Sarah HaydelHouma$265K
- Frankie RholdonLafayette$227K
- William MassengalePrairieville$225K
- Julie MermilliodNew Orleans$222K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.